Abstract 4340802: Right Ventricular Longitudinal Strain Indexed to Right Ventricular Systolic Pressure for Detecting Right Ventricular-Pulmonary Artery Uncoupling and Mortality in Pulmonary Hypertension Patients
Background: A key determinant of prognosis in pulmonary hypertension (PH) is the right ventricle’s (RV) ability to adapt to increased pulmonary vascular resistance. Consequently, markers of RV-pulmonary artery (PA) coupling may improve prognostic prediction in PH. The ratio of tricuspid annular plane systolic excursion (TAPSE) to systolic PA pressure (sPAP) has been proposed as a surrogate for RV-PA coupling and a reliable prognostic marker, however, the existing data on the prognostic value of the ratio between RV longitudinal strain (RVLS) and sPAP as a surrogate for RV-PA coupling is scarce. Hypothesis: To evaluate the prognostic role of RVLS/RVSP in PH patients and to compare this novel marker with established markers of RV-PA coupling. Methods: This is a single-center study that included adult patients with PH classified as group I or IV, all of whom had undergone a transthoracic echocardiogram (TTE) within one year prior to the initiation of PH-specific treatment. Certified sonographers procured RV strain measurements using a specific software (Epsilon Imaging, Ann Arbor, MI). Receiver operating characteristic (ROC) analysis was used to determine the best cutoff for predicting all-cause mortality at one-year for RVLS/RVSP and TAPSE/RVSP. The association of RVLS/RVSP and TAPSE/RVSP with mortality at one year was assessed using the Kaplan-Meier analysis and multivariate Cox regression analysis (adjusted for REVEAL LITE 2.0 risk score). Results: A total of 160 patients were included with a median age of 67.2 (56.8, 73.7) years and 47 (29.2%) were male . ROC analysis revealed optimal cutoffs of 0.265 (AUC = 0.83) for RVLS/RVSP and 0.185 (AUC = 0.77) for TAPSE/RVSP to predict all-cause mortality at one year. One-year cumulative incidence of all-cause mortality was lower among patients with RVLS/RVSP ≥ 0.265 (0 % vs 13.7 %, p = 0.001) and patients with TAPSE/RVSP ≥ 0.185 (1.8 % vs 16.7 %, p = 0.001) (Figure 1) . In the multivariate analysis, RVLS/RVSP < 0.265 was associated with higher risk of mortality at one year (HR: 2.38, 95 % CI: 1.05 to 5.38, p = 0.036) while TAPSE/RVSP < 0.185 was not (HR: 2.01, 95 % CI: 0.93 to 4.31, p = 0.072). Conclusions: RVLS/ RVSP may be a valuable prognostic marker in PH patients and could outperform conventional TTE parameters as a surrogate for detecting RV-PA coupling.
Authors
- Hesham Sheashaa
- Milagros Pereyra (ORCID: https://orcid.org/0000-0003-4695-8436)
- Chadi Ayoub (ORCID: https://orcid.org/0000-0001-5877-7478)
- Ahmed K. Mahmoud
- Reza Arsanjani (ORCID: https://orcid.org/0000-0001-7081-4286)
- Isabel G. Scalia (ORCID: https://orcid.org/0000-0002-6459-9767)
- Nobuhisa Baba
- Kamal Awad (ORCID: https://orcid.org/0000-0001-6707-1629)
- Juan Farina (ORCID: https://orcid.org/0000-0002-5824-8485)
- Christy M. Baxter
- Nadera N. Bismee
- Rachel Wraith
- Fatmaelzahraa E. Abdelfattah (ORCID: https://orcid.org/0009-0008-0758-1086)
- Arshad Mohammed (ORCID: https://orcid.org/0000-0002-8555-1287)
- Mohammed Tiseer Abbas
- Lisa Brown (ORCID: https://orcid.org/0000-0001-7840-568X)
- Sogol Attaripour Esfahani
- Robert L. Scott
- Omar Ibrahim (ORCID: https://orcid.org/0009-0003-2530-7850)
- Timothy Barry
Institutions
- Mayo Clinic Hospital (US)
Publication Details
- Journal
- Circulation
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1161/circ.152.suppl_3.4340802
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00